COSCIENS Competitors

Stocks . USA . 
Stock . COSCIENS Biopharma
CSCI Stock   2.05  0.05  2.38%   
COSCIENS Biopharma competes with Biora Therapeutics, CervoMed, and Tvardi Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing COSCIENS Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of COSCIENS Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out COSCIENS Biopharma Correlation with its peers.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

COSCIENS Biopharma vs Kineta Correlation

Moving against COSCIENS Stock

  0.68DSGN Design TherapeuticsPairCorr
  0.47IMMP Immutep Ltd ADRPairCorr
  0.42ENGN enGene Holdings CommonPairCorr
  0.3663E ONWARD MEDICAL BVPairCorr
  0.34ALT AltimmunePairCorr
The current Return On Tangible Assets is estimated to decrease to -0.41. The current Return On Capital Employed is estimated to decrease to -0.89. As of now, COSCIENS Biopharma's Total Current Assets are increasing as compared to previous years.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of COSCIENS Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.102.0516.48
Details
Intrinsic
Valuation
LowRealHigh
0.101.9816.41
Details

COSCIENS Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between COSCIENS Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of COSCIENS and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of COSCIENS Biopharma does not affect the price movement of the other competitor.

High positive correlations

TNFA
+ 0.69
CRVO
OMGA
+ 0.6
CHRO
TNFA
+ 0.48
OMGA
TVRD
+ 0.17
TSBX
TNFA
+ 0.12
CHRO
OMGA
+ 0.09
CRVO
  

High negative correlations

OMGA
- 0.48
TSBX
CHRO
- 0.47
TSBX
TNFA
- 0.33
TSBX
CRVO
- 0.24
TSBX
TNFA
- 0.15
TVRD
TVRD
- 0.15
CHRO

Risk-Adjusted Indicators

There is a big difference between COSCIENS Stock performing well and COSCIENS Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze COSCIENS Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare COSCIENS Biopharma and related stocks such as Biora Therapeutics, Turnstone Biologics Corp, and CervoMed Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AGraham Number
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
20102011201220132014201520162017201820192020202120222023202420252026
CRVO200 K(22.6 M)(6.9 M)(2.5 M)(14.4 M)(6.7 M)(18 M)(1.4 M)(18.4 M)(11.8 M)(14.2 M)(24.1 M)(15.6 M)(2.2 M)(16.3 M)(14.7 M)(13.9 M)
TVRD8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M8.4 M(88.4 M)(85.5 M)(118.5 M)(70.9 M)(63.8 M)(67 M)

COSCIENS Biopharma and related stocks such as Biora Therapeutics, Turnstone Biologics Corp, and CervoMed Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in COSCIENS Biopharma financial statement analysis. It represents the amount of money remaining after all of COSCIENS Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

COSCIENS Biopharma Competitive Analysis

The better you understand COSCIENS Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, COSCIENS Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across COSCIENS Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CSCI BIOR TSBX CRVO CHRO TVRD OMGA TNFA
 2.38 
 2.05 
COSCIENS
 0.00 
 0.22 
Biora
 0.00 
 0.36 
Turnstone
 3.58 
 5.50 
CervoMed
 8.20 
 16.50 
Chromocell
 2.69 
 3.82 
Tvardi
 21.25 
 0.05 
Omega
 9.72 
 5.20 
TNF
Market Volatility
(90 Days Market Risk)
Abnormally volatile
Very steady
Very steady
Slightly risky
Very steady
Relatively risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Weak
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Moderate
Risky
Hazard
Small
Hazard
Strong
Hazard
Hazard
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Not Rated
Hold
Not Rated
Hold
Not Rated
Not Rated
Current Ratio
N/A
1.69 X
N/A
N/A
N/A
N/A
13.46 X
N/A
Net Asset
35.07 M
31.21 M
40.14 M
43.08 M
1.37 M
43.83 M
204.37 M
21.42 M
Profit Margin
(2.00) %
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(13.49 M)
(114.05 M)
(68.97 M)
(18.23 M)
(7.57 M)
(62.6 M)
(93.49 M)
(23.36 M)
Operating Margin
(0.86) %
N/A
N/A
(24.94) %
N/A
N/A
(6.29) %
N/A
Current Valuation
1.31 M
38.44 M
(8.06 M)
21.93 M
91.42 M
221.23 M
100.44 M
5.9 M
Price To Book
1.17 X
N/A
0.56 X
1.89 X
4.11 X
N/A
0.23 X
1.26 X
Retained Earnings
(12.11 M)
(950.96 M)
(247.59 M)
(70.73 M)
(21.47 M)
(755.61 M)
(334.63 M)
(129.14 M)
Current Asset
N/A
667 K
N/A
N/A
317 K
N/A
N/A
N/A
Beta
1.85
1.28
1.37
-6.23
N/A
N/A
1.64
2.28
Number Of Employees
40
58
14
15
4
12
93
6
Shares Outstanding
3.18 M
4.52 M
23.14 M
9.25 M
6.6 M
9.36 M
55.37 M
1.85 M
Cash Flow From Operations
(14.57 M)
(48.5 M)
(67.44 M)
(16.53 M)
(5.79 M)
(60.92 M)
(91.51 M)
(8.98 M)
Total Debt
2.31 M
47.43 M
1.19 M
3.88 M
2.19 M
44.45 M
128.43 M
10.58 K
Return On Equity
-1.13
N/A
-1.27
-0.71
N/A
N/A
-1.67
-1.15
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.17
-1.25
-0.58
-0.43
-1.89
N/A
-0.25
-0.24
Number Of Shares Shorted
9.91 K
258.12 K
281.36 K
193.62 K
76.91 K
547.71 K
5.21 M
5.72 M
Book Value Per Share
2.23 X
(36.43) X
0.64 X
2.81 X
(6.79) X
(5.29) X
0.21 X
17.47 X
Current Liabilities
N/A
3.01 M
N/A
N/A
166 K
N/A
N/A
N/A
Total Asset
35.07 M
31.21 M
40.14 M
43.08 M
1.37 M
43.83 M
204.37 M
21.42 M
Short Ratio
1.67 X
2.37 X
1.27 X
3.55 X
0.88 X
0.26 X
6.97 X
0.07 X
Target Price
N/A
34.0
1.0
22.43
8.5
56.2
11.5
N/A
Debt To Equity
N/A
N/A
N/A
N/A
N/A
N/A
0.15 %
N/A
Shares Owned By Institutions
8.93 %
36.00 %
51.49 %
23.98 %
13.60 %
2.76 %
87.75 %
0.29 %
Market Capitalization
8.64 M
1.86 M
8.21 M
49.13 M
8.9 M
242.26 M
7.9 M
6.48 M
Price To Sales
0.92 X
1.49 X
2.13 X
7.98 X
N/A
N/A
0.98 X
N/A
Net Income
(15.31 M)
(124.11 M)
(70.84 M)
(16.29 M)
(7.96 M)
(70.87 M)
(97.43 M)
(23.36 M)
Earnings Per Share
(6.54) X
0.36 X
(2.04) X
(2.90) X
(12.00) X
(2.25) X
(1.32) X
(202.00) X
Shares Owned By Insiders
1.48 %
0.10 %
7.69 %
32.16 %
53.88 %
27.53 %
1.60 %
0.01 %
Revenue
13.78 M
4 K
N/A
9.74 M
N/A
7.14 M
3.09 M
N/A
Working Capital
16.76 M
(43.9 M)
26.02 M
39.2 M
(2.71 M)
22.88 M
63.08 M
2.71 M
Cash And Equivalents
N/A
37.06 M
N/A
N/A
N/A
N/A
173.66 M
N/A
Cash Per Share
N/A
0.19 X
N/A
N/A
N/A
N/A
3.63 X
N/A
Gross Profit
4.42 M
1.25 M
(55.63 M)
(16.91 M)
272.31 K
N/A
(34.5 M)
N/A
Day Typical Price
2.05
0.22
0.36
5.42
15.93
3.75
0.0448
6.11
Accumulation Distribution
0.0049
N/A
N/A
7799.29
0.22
3788.0
0.28
0.53
Market Facilitation Index
0.01
N/A
N/A
0.0
3.77
0.0
0.014
4.74
Daily Balance Of Power
(5.00)
0.0
0.0
0.5588
0.3316
0.3571
0.6071
(0.12)
Period Momentum Indicator
(0.05)
N/A
N/A
0.19
1.25
0.1
0.0085
(0.56)
Rate Of Daily Change
0.98
1.0
1.0
1.04
1.08
1.03
1.21
0.9
Day Median Price
2.05
0.22
0.36
5.38
15.65
3.71
0.043
6.57
Price Action Indicator
(0.03)
N/A
N/A
0.22
1.48
0.16
0.0098
(1.65)
Coefficient Of Variation
11026.91
N/A
1864.69
(1,737)
2216.27
(2,482)
1837.69
(1,970)
Mean Deviation
6.67
N/A
2.57
3.47
5.31
2.78
22.28
8.7
Jensen Alpha
0.1205
N/A
0.2044
(0.32)
0.3865
(0.27)
1.68
(0.73)
Total Risk Alpha
(1.43)
N/A
(0.22)
(0.78)
(0.57)
(0.56)
(1.85)
(2.13)
Sortino Ratio
0.002
N/A
0.02
N/A
0.0478
N/A
0.0659
N/A
Downside Variance
201.62
N/A
26.08
N/A
37.71
N/A
669.27
N/A
Standard Deviation
14.03
N/A
3.74
4.61
8.68
3.62
33.11
13.16
Kurtosis
7.24
N/A
1.62
1.25
12.37
0.4439
2.08
4.59
Potential Upside
27.11
N/A
6.06
6.84
10.27
5.59
72.73
17.75
Treynor Ratio
(3.19)
N/A
(1.23)
(0.54)
(6.96)
(0.12)
1.45
(1.18)
Maximum Drawdown
94.83
N/A
21.24
19.42
68.9
17.9
155.58
79.44
Variance
196.8
N/A
14.0
21.22
75.33
13.13
1096.57
173.1
Market Risk Adjusted Performance
(3.18)
N/A
(1.22)
(0.53)
(6.95)
(0.11)
1.46
(1.17)
Risk Adjusted Performance
0.0167
N/A
0.0509
(0.04)
0.0453
(0.02)
0.0534
(0.03)
Skewness
1.37
N/A
0.1454
0.4318
2.35
0.2335
0.9848
1.32
Semi Deviation
11.28
N/A
3.05
N/A
5.79
N/A
23.86
N/A
Information Ratio
0.0021
N/A
0.0274
(0.08)
0.0338
(0.07)
0.0514
(0.06)
Value At Risk
(28.04)
N/A
(6.06)
(7.29)
(10.69)
(5.95)
(52.09)
(20.86)
Expected Short fall
(8.28)
N/A
(4.24)
N/A
(7.41)
N/A
(31.18)
N/A
Downside Deviation
14.2
N/A
5.11
N/A
6.14
N/A
25.87
N/A
Semi Variance
127.21
N/A
9.28
N/A
33.54
N/A
569.52
N/A

COSCIENS Biopharma Competition Performance Charts

Five steps to successful analysis of COSCIENS Biopharma Competition

COSCIENS Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by COSCIENS Biopharma in relation to its competition. COSCIENS Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of COSCIENS Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact COSCIENS Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to COSCIENS Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your COSCIENS Biopharma position

In addition to having COSCIENS Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Single Stock ETFs Thematic Idea Now

Single Stock ETFs
Single Stock ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Single Stock ETFs theme has 432 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Single Stock ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
How To Invest In COSCIENS
Details
Is COSCIENS Stock a good investment?
Details
What is COSCIENS Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out COSCIENS Biopharma Correlation with its peers.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.54)
Revenue Per Share
2.996
Quarterly Revenue Growth
0.176
Return On Assets
(0.17)
Return On Equity
(1.13)
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY